Study identifier:CIN-107-123
ClinicalTrials.gov identifier:NCT05432167
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
Uncontrolled Hypertension
Phase 2
No
CIN-107, Placebo
All
194
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
PAREXEL
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Low dose CIN-107 Patients will take oral tablets of CIN-107 for 26 weeks. The dose strength may be titrated within 6 weeks. | Drug: CIN-107 Patients will take CIN-107 tablets by mouth once daily. |
Experimental: High dose CIN-107 Patients will take oral tablets of CIN-107 for 26 weeks. The dose strength may be titrated within 6 weeks. | Drug: CIN-107 Patients will take CIN-107 tablets by mouth once daily. |
Placebo Comparator: Placebo Patients will take oral tablets of Placebo for 26 weeks. The dose strength may be titrated within 6 weeks. | Drug: Placebo Patients will take placebo tablets by mouth once daily. |